Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Taki who wrote (58453)	8/8/2000 11:57:36 AM
From: Mr.Manners	Respond to of 150070

EBAS looking good

To: Taki who wrote (58453)	8/8/2000 12:02:00 PM
From: Taki	Read Replies (1) \| Respond to of 150070

Big news on STGI. (BSNS WIRE) STGI Acquires Drug Patent Rights That May Be 'Most Lucrative' STGI Acquires Drug Patent Rights That May Be 'Most Lucrative' Business Editors/Health & Medical Writers LAS VEGAS--(BUSINESS WIRE)--Aug. 8, 2000--(OTCBB:STGI-news) Steroidogenesis Inhibitors International, Inc. is pleased to announce that it has purchased U.S. Patent No. 4,956391. This patent is a "Protected complex of Procaine for the treatment of symptoms from Narcotics Addiction, Tinnitus and Alzheimer's disease." It is part of a drug composition, which is comprised of a protected complex of Procaine and another agent, similar to Anticort. (TM) Therefore, this is considered extremely valuable to STGI since it is already granted. The award of the pioneering patent for the use of Procaine as an anticortisol may prove to be the most lucrative yet, in as much as this patent was granted in September 1990 and has seven years left on it. This patent (invention), which had lapsed due to non-payment of filing fees, was assigned to its owner and now seller, as a settlement in a lawsuit and had to be reinstated. STGI paid the filing fees to get it reinstated, which was granted. Ms. Johnson, the seller stated "I am personally thrilled that after an arduous 10 year legal battle, I was awarded 100% rights to this coveted patent. I eagerly look forward to getting this needed treatment to the market to help those who are suffering from these maladies, particularly Alzheimer's." She further stated "I feel honored to be working with Dr. Janet Greeson, Bert Wollen and Eugene Boyle and have all the confidence in the world that they are capable of ensuring distribution of this drug to the world in a competent and efficient manner." Dr. Janet Greeson, president of STGI stated " I am very excited about this, strengthening our intellectual property estate is the primary factor in creating and protecting the value of STGI for its shareholders." STGI currently has three patent applications that are being pursued at this time 1. U.S Patent Application-Composition of Anti-HIV Drugs and Anticortisol Compounds and Method for Decreasing the Side Effects of Anti-HIV Drugs in a Human, filed 1/21/99. 2. U.S. Patent Application-Circadian Rhythm Cortisol Chart and Method of Use Thereof, claiming priority to a Provisional Patent Application, filed 11/7/98. 3. PCT Application-Composition of Anti-HIV Drugs and Anticortisol Compounds and Method for Decreasing the Side Effects of Anti-HIV Drugs in a Human, filed 1/20/00. STGI is a pharmaceutical company with its core technology being ANTICORT(TM), which is currently in FDA Phase 1B/2A clinical trials as an anticortisol drug for the treatment of HIV positives. This Release Contains Statements About the Future That Could Differ From Actual Results. the Statements are Subject to Risk and Uncertainties, Including, But Not Limited To, the Impact of Competition, Fluctuations in Stock Price and Liquidity, Fluctuating Operating Results and Other Risks. --30--JD/ph* CONTACT: Steroidogenesis Inhibitors, Intl Dr. Janet Greeson, 702/222-1988 email GreesonJan@aol.com anticort.com by Columbia Financial Group Brokers and Analysts contact: 888/301-6271 or Performance Strategies, Inc. Richard L. Brown or Chuck Jordan, 303/948-3601